Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)
NIH will fund milestone-driven technology development and validation projects to create or adapt senescence technologies for identifying, characterizing, and understanding senescent cell heterogeneity and its biological effects in tissues and disease, with a collaborative demonstration phase in SenNet.
⚑ UG3/UH3 cooperative agreement; milestone-driven, non-automatic transition from UG3 to UH3 after Year 2 administrative review · Clinical Trial Not Allowed · Applicants must submit UG3 and UH3 projects together · Foreign entities are eligible; other listed eligible applicant classes include tribal governments, federal agencies, U.S. territories, faith-based/community organizations, and regional organizations
This is a biomedical technology-development call focused on cellular senescence measurement and modulation, which is far outside IPPRA’s social-behavioral, policy, risk, and public-opinion portfolio. None of the listed researchers’ core programs align with the biology or translational lab technology required here.
JUDGED AGAINST THE ROSTER'S PUBLICATION DOSSIER · GPT-5.4-MINI · 2026-10-10
Unit fits — one characterization, each unit's own rules
| Physical Sciences & Engineering (demo) | 80 strong | technical depth: substantial; funds applied research |
| IPPRA | 45 partial | peripheral portfolio topic: environment; social/behavioral work is none; funds applied research; biomedical core — IPPRA health lane is communication/crisis/policy (capped); capped at 45 (limited social-science role) |
| Tom Love Innovation Hub | 45 partial | funds applied research; prototyping/demonstration stage; deep-tech content |
Description
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit the development of innovative senescence technologies (SenTecs), or the adaptation of existing technologies focused on identification, characterization and understanding the biological consequences of senescent cell (SnC) heterogeneity in the context of the tissue environments and secretomes to facilitate novel strategies for modulating SnCs in vivo and for predicting the outcomes of targeting SnCs in human aging and in disease conditions. These are five-year, milestone-driven awards consisting of two phases. The first two years constitute the UG3 phase and are focused on SenTec development and demonstration of technology feasibility. The following 3-years is the SenTec application UH3 phase where SenTecs continue to be optimized, refined and validated. In the final year of the UH3 award, SenTecs will undertake a demonstration project conducted in a collaborative effort within SenNet to provide further validation of the proposed SenTec. Applicants are required to submit both UG3 and UH3 projects together when responding to this NOFO. Transition from the UG3 to UH3 phases is not automatic and will occur only after administrative review of each SenTec at the close of Year 2 of the award.
Eligibility
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Apply
View on Grants.gov → CONTACT: National Institutes of Health <CS2@nih.gov>
Proposal brief SEE AN EXAMPLE →
A one-page internal memo: fit assessment, submission requirements, document scaffold, and next steps dated back from the deadline — tailored to your project idea if you add one.
Proposal shell · National Institutes of Health conventions SEE AN NIH EXAMPLE →
Funder-faithful document skeletons — National Institutes of Health's document set with section headings, page limits, reviewer guidance, and writing prompts; add a project idea to get [DRAFT] starter bullets. Download as .md for Word or Overleaf.